Preliminary human studies using [18F]AV-1451 have been used to follow MCI and AD progression over relatively short periods of time (up to 19 months), and have shown significant rises in tau signals over time as symptoms progress, indicating the potential for tau tracers to detect disease progression [57]. The gene discussed is MAPT; the disease is Alzheimer disease.